Cidara Therapeutics logo

Cidara TherapeuticsNASDAQ: CDTX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

15 April 2015

Next earnings report:

22 April 2025

Last dividends:

N/A

Next dividends:

N/A
$106.54 M
-39%vs. 3y high
46%vs. sector
-vs. 3y high
-vs. sector
-92%vs. 3y high
37%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | Wed, 20 Nov 2024 21:00:02 GMT
$15.12-$0.62(-3.94%)

Dividend

No data over the past 3 years

Analysts recommendations

Institutional Ownership

CDTX Latest News

Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
globenewswire.com07 November 2024 Sentiment: POSITIVE

SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the third quarter ended September 30, 2024, and provided an update on its corporate activities and product pipeline.

Cidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza Conference
globenewswire.com25 September 2024 Sentiment: POSITIVE

SAN DIEGO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced two presentations at OPTIONS XII for the Control of Influenza conference, to be held September 29 through October 2, 2024 in Brisbane, Australia. The presentations, one oral and one poster, will highlight safety and pharmacokinetic (PK) data from clinical studies of CD388, Cidara's influenza drug-Fc conjugate (DFC) candidate.

Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza
globenewswire.com23 September 2024 Sentiment: POSITIVE

The Phase 2b trial will enroll 5,000 subjects across clinical sites in the US and UK The Phase 2b trial will enroll 5,000 subjects across clinical sites in the US and UK

Cidara Therapeutics Strengthens its Scientific Advisory Board with Infectious Disease Experts
globenewswire.com19 September 2024 Sentiment: POSITIVE

SAN DIEGO, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the appointment of Rick Bright, Ph.D., Philip Krause, M.D., Mario Barro, Ph.D., and Frederick G. Hayden, M.D., FACP to its Scientific Advisory Board (SAB).

Cidara Therapeutics Restructures Workforce to Focus on Planned Clinical Development of CD388
globenewswire.com12 September 2024 Sentiment: NEUTRAL

SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced a reduction in its workforce to focus on the clinical development of CD388, the Company's novel DFC candidate for influenza A and B. The planned reduction impacts approximately 30% of the Cidara workforce.

Cidara Therapeutics Announces Appointment of Jim Beitel as Chief Business Officer
globenewswire.com19 August 2024 Sentiment: POSITIVE

Appointment adds biotech veteran with over two decades of business development, strategy, and operational experience to Cidara's management team Appointment adds biotech veteran with over two decades of business development, strategy, and operational experience to Cidara's management team

Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
globenewswire.com13 August 2024 Sentiment: POSITIVE

SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the second quarter ended June 30, 2024, and provided an update on its corporate activities and product pipeline.

Cidara Therapeutics shares surge 30% after reacquiring flu treatment
Market Watch24 April 2024 Sentiment: POSITIVE

Cidara Therapeutics shares surged following the company's announcement of changes to its drug candidate lineup.

Cidara (CDTX) Up on EC Nod for Rezzayo in Invasive Candidiasis
Zacks Investment Research26 December 2023 Sentiment: POSITIVE

Cidara's (CDTX) Rezzayo (rezafungin acetate) gets approval from the European Commission for the treatment of invasive candidiasis in adults. The stock rises 11.1%.

Cidara Therapeutics to Present New Preclinical Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress
GlobeNewsWire30 November 2023 Sentiment: POSITIVE

Preclinical data on dual CD73/PD-1 targeting DFC to be presented for the first time Preclinical data on dual CD73/PD-1 targeting DFC to be presented for the first time

What type of business is Cidara Therapeutics?

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

What sector is Cidara Therapeutics in?

Cidara Therapeutics is in the Healthcare sector

What industry is Cidara Therapeutics in?

Cidara Therapeutics is in the Biotechnology industry

What country is Cidara Therapeutics from?

Cidara Therapeutics is headquartered in United States

When did Cidara Therapeutics go public?

Cidara Therapeutics initial public offering (IPO) was on 15 April 2015

What is Cidara Therapeutics website?

https://www.cidara.com

Is Cidara Therapeutics in the S&P 500?

No, Cidara Therapeutics is not included in the S&P 500 index

Is Cidara Therapeutics in the NASDAQ 100?

No, Cidara Therapeutics is not included in the NASDAQ 100 index

Is Cidara Therapeutics in the Dow Jones?

No, Cidara Therapeutics is not included in the Dow Jones index

When was Cidara Therapeutics the previous earnings report?

No data

When does Cidara Therapeutics earnings report?

The next expected earnings date for Cidara Therapeutics is 22 April 2025